Drugs / InfanrixTM hexa
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00891176 | May 2009 → Nov 2012 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00258154 | Feb → Nov 2006 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Infanrix(tm) Hexa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00258154 ↗ |
| Known as | INFANRIX Hexa | “V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)” NCT00258154 ↗ |
| Modality | Vaccine | “hexavalent vaccine containing diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b” PMID 19209092 ↗ Mar 2009 |
| Route | Oral | “3 doses of oral Infanrix(tm) Hexa on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2” NCT00258154 ↗ |